Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.46 |
| ▸ | AGT | P01019 | 2/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.36 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGAV | P06756 | 1/20 | 0.34 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2831924 | 1.00 | AGTR1 (0.46) | AGTR1AGTR2AGTCD274ADAMTS4 | |
| Hydrochloric Acid SCHEMBL2829155 | 0.99 | AGTR1 (0.45) | AGTR1AGTR2AGTCD274ADAMTS4 | |
| Hydrochloric Acid SCHEMBL2829151 | 0.99 | AGTR1 (0.45) | AGTR1AGTR2AGTCD274ADAMTS4 | |
| SCHEMBL8233626 | 0.92 | AGTR1 (0.44) | AGTR1AGTR2AGTCD274HCRTR2 | |
| SCHEMBL5181662 | 0.92 | AGTR1 (0.40) | AGTR1AGTR2AGTCD274ADAMTS4 | |
| SCHEMBL29669891 | 0.92 | AGTR1 (0.44) | AGTR1AGTR2AGTCD274HCRTR2 | |
| SCHEMBL1261649 | 0.92 | AGTR1 (0.44) | AGTR1AGTR2AGTCD274HCRTR2 | |
| SCHEMBL5181666 | 0.92 | AGTR1 (0.40) | AGTR1AGTR2AGTCD274ADAMTS4 | |
| Hydrochloric Acid SCHEMBL5181038 | 0.91 | AGTR1 (0.40) | AGTR1AGTR2AGTCD274ADAMTS4 | |
| Hydrochloric Acid SCHEMBL5181031 | 0.91 | AGTR1 (0.40) | AGTR1AGTR2AGTCD274ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140316142-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF | ALKEM LABORATORIES LTD. (IN) | 2014-10-23 | — | — | US | disclosed |
| EP-1831186-B1 | A PROCESS FOR THE SYNTHESIS OF VALSARTAN | KRKA D D NOVO MESTO (SI) | 2010-07-28 | — | — | EP | disclosed |
| EP-1661891-A1 | A process for the synthesis of valsartan | KRKA, D.D., Novo Mesto (SI) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140316142-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF | AGTR1, AGTR2, AVPR2 | AGTR1 1/4885AGTR2 2/4885AGT 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.